Are Irish eyes smiling on generic substitution, reference pricing?

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.607, 2010-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib: one step closer to value-based pricing?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 533, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Reflections on the Changing Face of German Pharmaceutical Policy: How Far is Germany from Value-Based Pricing?

By Gerber Andreas

PharmacoEconomics, Vol. 29, Iss. 7, 2011-07 ,pp. : 549-553

Adis International

Access to resources Recommend Favorite

Do reference-based pricing policies really contain drug costs?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 320, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Reference-based drug pricing in Canada in need of fine-tuning?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 394, 2003-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Reference pricing or HTA for obtaining best value from drugs?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 540, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite